{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:07:59Z","timestamp":1794348479294,"version":"4.9.0"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"DOI":"10.1186\/s12987-026-00760-2","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T05:23:58Z","timestamp":1770441838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Bridging the blood-brain barrier: strategies to improve delivery of biologics to tumors in the brain"],"prefix":"10.1186","volume":"23","author":[{"given":"Gautham","family":"Gampa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Vadlakonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Stefanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita V.","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Sadekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittal","family":"Shivva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"1","key":"760_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: a Cancer J Clin. 2023;74(1):12\u201349.","journal-title":"CA: A Cancer J Clin"},{"issue":"Supplement_4","key":"760_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro-Oncol. 2023;25(Supplement_4):iv1\u201399.","journal-title":"Neuro-Oncol"},{"key":"760_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-811161-1.00002-5","volume":"149","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Wright CH, Barnholtz-Sloan JS. Brain metastases: epidemiology. Handb Clin Neurol. 2018;149:27\u201342.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"760_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","volume":"14","author":"L Nayak","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48\u201354.","journal-title":"Curr Oncol Rep"},{"key":"760_CR5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/B978-0-7020-4088-7.00077-8","volume":"121","author":"JG P\u00e9rez-Larraya","year":"2014","unstructured":"P\u00e9rez-Larraya JG, Hildebrand J. Neurologic aspects of systemic disease part III. Handb Clin Neurol. 2014;121:1143\u201357.","journal-title":"Handb Clin Neurol"},{"issue":"9","key":"760_CR6","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","volume":"23","author":"N Lamba","year":"2021","unstructured":"Lamba N, Wen PY, Aizer AA. Epidemiology of brain metastases and leptomeningeal disease. Neuro-Oncol. 2021;23(9):1447\u201356.","journal-title":"Neuro-Oncol"},{"issue":"2","key":"760_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/02841860500486630","volume":"45","author":"T Yau","year":"2006","unstructured":"Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 2006;45(2):196\u2013201.","journal-title":"Acta Oncol"},{"issue":"10","key":"760_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den BMJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"5","key":"760_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2021","unstructured":"Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol: Off J Am Soc Clin Oncol. 2021;40(5):492\u2013516.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"11","key":"760_CR10","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","volume":"18","author":"LB Nabors","year":"2020","unstructured":"Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, et al. Central nervous system cancers, version 3. 2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw: JNCCN. 2020;18(11):1537\u201370.","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"issue":"2","key":"760_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","volume":"20","author":"JN Sarkaria","year":"2018","unstructured":"Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncol. 2018;20(2):184\u201391.","journal-title":"Neuro-Oncol"},{"issue":"3","key":"760_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31(3):326\u201341.","journal-title":"Cancer Cell"},{"issue":"8","key":"760_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","volume":"16","author":"K Aldape","year":"2019","unstructured":"Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019;16(8):509\u201320.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"760_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4161\/mabs.3.2.14239","volume":"3","author":"LA Lampson","year":"2010","unstructured":"Lampson LA. Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. mAbs. 2010;3(2):153\u201360.","journal-title":"mAbs"},{"key":"760_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.phrs.2017.06.008","volume":"123","author":"G Gampa","year":"2017","unstructured":"Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF. Drug delivery to melanoma brain metastases: can current challenges lead to new opportunities? Pharmacol Res. 2017;123:10\u201325.","journal-title":"Pharmacol Res"},{"issue":"1","key":"760_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13550-015-0082-6","volume":"5","author":"H Kurihara","year":"2015","unstructured":"Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, et al. (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res. 2015;5(1):8.","journal-title":"EJNMMI Res"},{"key":"760_CR17","doi-asserted-by":"crossref","unstructured":"Azim HA Jr, HAA. Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions. Futur Oncol (lond, Engl). 2012;8(2):135\u201344.","DOI":"10.2217\/fon.11.149"},{"issue":"48","key":"760_CR18","doi-asserted-by":"publisher","first-page":"83734","DOI":"10.18632\/oncotarget.19634","volume":"8","author":"TB Terrell-Hall","year":"2017","unstructured":"Terrell-Hall TB, Nounou MI, El-Amrawy F, Griffith JIG, Lockman PR. Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer. Oncotarget. 2017;8(48):83734\u201344.","journal-title":"Oncotarget"},{"issue":"3","key":"760_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","volume":"36","author":"NJ Abbott","year":"2013","unstructured":"Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36(3):437\u201349.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"760_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"760_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/d41573-024-00041-3","volume":"23","author":"P Verdin","year":"2024","unstructured":"Verdin P. Top companies and drugs by sales in 2023. Nat Rev Drug Discov. 2024;23(4):240\u2013240.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"760_CR22","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1073\/pnas.91.12.5705","volume":"91","author":"JF Poduslo","year":"1994","unstructured":"Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci. 1994;91(12):5705\u201309.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"760_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s13311-013-0187-4","volume":"10","author":"YJ Yu","year":"2013","unstructured":"Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics. 2013;10(3):459\u201372.","journal-title":"Neurotherapeutics"},{"key":"760_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","volume":"11","author":"WM Pardridge","year":"2020","unstructured":"Pardridge WM. Blood-brain barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci. 2020;11:373.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"760_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/19420862.2018.1473910","volume":"10","author":"HY Chang","year":"2018","unstructured":"Chang HY, Morrow K, Bonacquisti E, Zhang W, Shah DK. Antibody pharmacokinetics in rat brain determined using microdialysis. mAbs. 2018;10(6):843\u201353.","journal-title":"mAbs"},{"issue":"1","key":"760_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12987-018-0093-6","volume":"15","author":"Q Wang","year":"2018","unstructured":"Wang Q, Delva L, Weinreb PH, Pepinsky RB, Graham D, Veizaj E, et al. Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration. Fluids Barriers CNS. 2018;15(1):10.","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"760_CR27","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41467-025-57108-x","volume":"16","author":"N Khoury","year":"2025","unstructured":"Khoury N, Pizzo ME, Discenza CB, Joy D, Tatarakis D, Todorov MI, et al. Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution. Nat Commun. 2025;16(1):1822.","journal-title":"Nat Commun"},{"issue":"4","key":"760_CR28","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/cpt.2531","volume":"111","author":"SS Sadekar","year":"2022","unstructured":"Sadekar SS, Bowen M, Cai H, Jamalian S, Rafidi H, Shatz-Binder W, et al. Translational approaches for brain delivery of biologics via cerebrospinal fluid. Clin Pharmacol Ther. 2022;111(4):826\u201334.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"760_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1208\/s12248-022-00701-5","volume":"24","author":"HY Chang","year":"2022","unstructured":"Chang HY, Wu S, Li Y, Guo L, Li Y, Shah DK. Effect of the size of protein therapeutics on brain pharmacokinetics following systematic administration. Aaps J. 2022;24(3):62.","journal-title":"Aaps J"},{"issue":"12","key":"760_CR30","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.3390\/ijms22126442","volume":"22","author":"A Kouhi","year":"2021","unstructured":"Kouhi A, Pachipulusu V, Kapenstein T, Hu P, Epstein AL, Khawli LA. Brain disposition of antibody-based therapeutics: dogma, approaches and perspectives. Int J Mol Sci. 2021;22(12):6442.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"760_CR31","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1073\/pnas.86.12.4761","volume":"86","author":"D Triguero","year":"1989","unstructured":"Triguero D, Buciak JB, Yang J, Pardridge WM. Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. Proc Natl Acad Sci. 1989;86(12):4761\u201365.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"760_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/10717549509031361","volume":"2","author":"U Bickel","year":"1995","unstructured":"Bickel U, Lee VMY, Pardridge WM. Pharmacokinetic differences between 111In- and 125I-labeled cationized monoclonal antibody against \u03b2-amyloid in mouse and dog. Drug Deliv. 1995;2(2):128\u201335.","journal-title":"Drug Deliv"},{"issue":"12","key":"760_CR33","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1021\/bc100261d","volume":"21","author":"CA Boswell","year":"2010","unstructured":"Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjugate Chem. 2010;21(12):2153\u201363.","journal-title":"Bioconjugate Chem"},{"issue":"24","key":"760_CR34","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.1158\/1078-0432.CCR-16-2035","volume":"22","author":"PS Steeg","year":"2016","unstructured":"Steeg PS, Zimmer A, Gril B. Therapeutics for brain metastases, v3. Clin Cancer Res. 2016;22(24):5953\u201355.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"760_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10585-016-9784-z","volume":"33","author":"CE Adkins","year":"2016","unstructured":"Adkins CE, Mohammad AS, Terrell-Hall TB, Dolan EL, Shah N, Sechrest E, et al. Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer. Clin Exp Metastasis. 2016;33(4):373\u201383.","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"760_CR36","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3171\/2013.3.JNS122226","volume":"119","author":"EK Nduom","year":"2013","unstructured":"Nduom EK, Yang C, Merrill MJ, Zhuang Z, Lonser RR. Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg. 2013;119(2):427\u201333.","journal-title":"J Neurosurg"},{"issue":"3","key":"760_CR37","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.tranon.2015.03.009","volume":"8","author":"DH Murrell","year":"2015","unstructured":"Murrell DH, Hamilton AM, Mallett CL, van GR, Chambers AF, Foster PJ. Understanding heterogeneity and permeability of brain metastases in murine models of HER2-positive breast cancer through magnetic resonance imaging: implications for detection and therapy. Transl Oncol. 2015;8(3):176\u201384.","journal-title":"Transl Oncol"},{"issue":"3","key":"760_CR38","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s11060-011-0564-y","volume":"104","author":"MW Pitz","year":"2011","unstructured":"Pitz MW, Desai A, Grossman SA, Blakeley JO. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neuro-Oncol. 2011;104(3):629\u201338.","journal-title":"J Neuro-Oncol"},{"issue":"11","key":"760_CR39","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/neuonc\/noaa118","volume":"22","author":"B Gril","year":"2020","unstructured":"Gril B, Wei D, Zimmer AS, Robinson C, Khan I, Difilippantonio S, et al. HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive marker. Neuro-Oncol. 2020;22(11):1625\u201336.","journal-title":"Neuro-Oncol"},{"key":"760_CR40","unstructured":"Kulic L, Alcaraz F, Klein G, Hofmann C, Yilmaz S, Abrantes JA, et al. Latest interim results from the Brainshuttle AD study, a phase 1b\/2a study of trontinemab in people with Alzheimer\u2019s disease. In Madrid, Spain. 2024. Available from: https:\/\/medically.gene.com\/global\/en\/unrestricted\/neuroscience\/CTAD-2024\/ctad-2024-presentation-kulic-latest-interim-results-fro.html?cid=slprxx2105rexxats2021%26;cid=slprxx2105rexxats2021."},{"issue":"2","key":"760_CR41","doi-asserted-by":"publisher","first-page":"107031","DOI":"10.1016\/j.ymgme.2022.107031","volume":"138","author":"A Bhalla","year":"2023","unstructured":"Bhalla A, Tsogtbaatar K, Ravi R, Fang M, Davis SS, Zubizarreta I, et al. DNL310 normalizes primary storage substrates and biomarkers of lysosomal dysfunction in neuronopathic MPS II: 2-year interim analysis of a phase 1\/2 study. Mol Genet Metab. 2023;138(2):107031.","journal-title":"Mol Genet Metab"},{"key":"760_CR42","unstructured":"Ciccone I. FDA grants breakthrough therapy designation to Denali\u2019s Tividenofusp alfa for hunter syndrome [Internet]. 2025. https:\/\/www.neurologylive.com\/view\/fda-grants-breakthrough-therapy-designation-denali-tividenofusp-alfa-hunter-syndrome. cited 2025 Nov 16]. Available from."},{"issue":"2","key":"760_CR43","first-page":"671","volume":"29","author":"T Okuyama","year":"2021","unstructured":"Okuyama T, Eto Y, Sakai N, Nakamura K, Yamamoto T, Yamaoka M, et al. A Phase 2\/3 trial of Pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody. Targeting Neurodegener In MPS-II. Mol Ther. 2021;29(2):671\u201379.","journal-title":"Targeting Neurodegener In MPS-II. Mol Ther"},{"issue":"3","key":"760_CR44","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ymthe.2024.01.009","volume":"32","author":"P Harmatz","year":"2024","unstructured":"Harmatz P, Giugliani R, Martins AM, Hamazaki T, Kubo T, Kira R, et al. \u03b1-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: a phase 1\/2 trial. Mol Ther. 2024;32(3):609\u201318.","journal-title":"Mol Ther"},{"key":"760_CR45","unstructured":"D-T. Denali therapeutics reports Third Quarter 2024 financial results and business highlights [Internet]. 2024. https:\/\/investors.denalitherapeutics.com\/news-releases\/news-release-details\/denali-therapeutics-reports-third-quarter-2024-financial-results. cited 2025 Nov 16]. Available from."},{"issue":"2","key":"760_CR46","first-page":"145","volume":"8","author":"HA Riina","year":"2009","unstructured":"Riina HA, Fraser JF, Fralin S, Knopman J, Scheff RJ, Boockvar JA. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol. 2009;8(2):145\u201350.","journal-title":"J Exp Ther Oncol"},{"issue":"3","key":"760_CR47","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3171\/2010.9.JNS101223","volume":"114","author":"JA Boockvar","year":"2010","unstructured":"Boockvar JA, Tsiouris AJ, Hofstetter CP, Kovanlikaya I, Fralin S, Kesavabhotla K, et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clin Article. J Neurosurg. 2010;114(3):624\u201332.","journal-title":"Clin Article. J Neurosurg"},{"issue":"1","key":"760_CR48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.wneu.2011.05.056","volume":"77","author":"JK Burkhardt","year":"2012","unstructured":"Burkhardt JK, Riina H, Shin BJ, Christos P, Kesavabhotla K, Hofstetter CP, et al. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg. 2012;77(1):130\u201334.","journal-title":"World Neurosurg"},{"issue":"11","key":"760_CR49","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.3174\/ajnr.A3091","volume":"33","author":"JY Jeon","year":"2012","unstructured":"Jeon JY, Kovanlikaya I, Boockvar JA, Mao X, Shin B, Burkhardt JK, et al. Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of Bevacizumab: a proton MR spectroscopic imaging study. Am J Neuroradiol. 2012;33(11):2095\u2013102.","journal-title":"Am J Neuroradiol"},{"issue":"4","key":"760_CR50","first-page":"261","volume":"11","author":"S Chakraborty","year":"2016","unstructured":"Chakraborty S, Filippi CG, Burkhardt JK, Fralin S, Ray A, Wong T, et al. Durability of single dose intra-arterial bevacizumab after blood\/brain barrier disruption for recurrent glioblastoma. J Exp Ther Oncol. 2016;11(4):261\u201367.","journal-title":"J Exp Ther Oncol"},{"issue":"3","key":"760_CR51","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11060-016-2099-8","volume":"128","author":"S Chakraborty","year":"2016","unstructured":"Chakraborty S, Filippi CG, Wong T, Ray A, Fralin S, Tsiouris AJ, et al. Superselective intraarterial cerebral infusion of cetuximab after osmotic blood\/brain barrier disruption for recurrent malignant glioma: phase I study. J Neuro-Oncol. 2016;128(3):405\u201315.","journal-title":"J Neuro-Oncol"},{"issue":"2","key":"760_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11060-021-03851-2","volume":"155","author":"NV Patel","year":"2021","unstructured":"Patel NV, Wong T, Fralin SR, Li M, McKeown A, Gruber D, et al. Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I\/II clinical trial. J Neuro-Oncol. 2021;155(2):117\u201324.","journal-title":"J Neuro-Oncol"},{"key":"760_CR53","doi-asserted-by":"crossref","unstructured":"Woodworth GF, Anastasiadis P, Chen C, Gandhi D, Ozair A, Meng Y, et al. Acoustic emissions dose and spatial control of blood-brain barrier opening with focused ultrasound. 2025.","DOI":"10.2139\/ssrn.5080353"},{"issue":"1","key":"760_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMoa2308719","volume":"390","author":"AR Rezai","year":"2024","unstructured":"Rezai AR, D\u2019Haese PF, Finomore V, Carpenter J, Ranjan M, Wilhelmsen K, et al. Ultrasound blood-brain barrier opening and Aducanumab in Alzheimer\u2019s disease. N Engl J Med. 2024;390(1):55\u201362.","journal-title":"N Engl J Med"},{"issue":"1","key":"760_CR55","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1038\/s41467-024-48326-w","volume":"15","author":"VA Arrieta","year":"2024","unstructured":"Arrieta VA, Gould A, Kim KS, Habashy KJ, Dmello C, V\u00e1zquez-Cervantes GI, et al. Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas. Nat Commun. 2024;15(1):4698.","journal-title":"Nat Commun"},{"issue":"5","key":"760_CR56","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","volume":"24","author":"AM Sonabend","year":"2023","unstructured":"Sonabend AM, Gould A, Amidei C, Ward R, Schmidt KA, Zhang DY, et al. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 2023;24(5):509\u201322.","journal-title":"Lancet Oncol"},{"key":"760_CR57","unstructured":"Delsona. Delsona UltraNav Pipeline [Internet]. 2025. https:\/\/delsona.com\/pipeline\/. cited 2025 Jan 22]. Available from."},{"issue":"Supplement_5","key":"760_CR58","doi-asserted-by":"publisher","first-page":"v91","DOI":"10.1093\/neuonc\/noad179.0345","volume":"25","author":"KC Wei","year":"2023","unstructured":"Wei KC. CTNI-63. A Phase iia clinical trial for combination of navigation-guide focused ultrasound and bevacizumab for patients with recurrent glioblastoma. Neuro-Oncol. 2023;25(Supplement_5):v91\u201391.","journal-title":"Neuro-Oncol"},{"issue":"6","key":"760_CR59","doi-asserted-by":"publisher","first-page":"eabd 0772","DOI":"10.1126\/sciadv.abd0772","volume":"7","author":"KT Chen","year":"2021","unstructured":"Chen KT, Chai WY, Lin YJ, Lin CJ, Chen PY, Tsai HC, et al. Neuronavigation-guided focused ultrasound for transcranial blood-brain barrier opening and immunostimulation in brain tumors. Sci Adv. 2021;7(6):eabd 0772.","journal-title":"Sci Adv"},{"issue":"6","key":"760_CR60","doi-asserted-by":"publisher","first-page":"e002296","DOI":"10.1136\/jitc-2020-002296","volume":"9","author":"J Duerinck","year":"2021","unstructured":"Duerinck J, Schwarze JK, Awada G, Tijtgat J, Vaeyens F, Bertels C, et al. Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial. J Immunother Cancer. 2021;9(6):e002296.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"760_CR61","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/ph17080973","volume":"17","author":"NW Rolfe","year":"2024","unstructured":"Rolfe NW, Dadario NB, Canoll P, Bruce JN. A review of therapeutic agents given by convection-enhanced delivery for adult glioblastoma. Pharmaceuticals. 2024;17(8):973.","journal-title":"Pharmaceuticals"},{"issue":"6","key":"760_CR62","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/neuonc\/noac285","volume":"25","author":"JH Sampson","year":"2023","unstructured":"Sampson JH, Achrol AS, Aghi MK, Bankiewicz K, Bexon M, Brem S, et al. Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: results of a phase IIb trial. Neuro-Oncol. 2023;25(6):1085\u201397.","journal-title":"Neuro-Oncol"},{"issue":"8","key":"760_CR63","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/neuonc\/nop054","volume":"12","author":"S Kunwar","year":"2010","unstructured":"Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma\u2020. Neuro-Oncol. 2010;12(8):871\u201381.","journal-title":"Neuro-Oncol"},{"issue":"4","key":"760_CR64","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/neuonc\/nop047","volume":"12","author":"A Carpentier","year":"2010","unstructured":"Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barri\u00e9 M, et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro-Oncol. 2010;12(4):401\u201308.","journal-title":"Neuro-Oncol"},{"issue":"1","key":"760_CR65","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/pharmaceutics13010040","volume":"13","author":"CD Nwagwu","year":"2020","unstructured":"Nwagwu CD, Immidisetti AV, Bukanowska G, Vogelbaum MA, Carbonell AM. Convection-enhanced delivery of a first-in-class anti-\u03b21 integrin antibody for the treatment of high-grade glioma utilizing real-time imaging. Pharmaceutics. 2020;13(1):40.","journal-title":"Pharmaceutics"},{"key":"760_CR66","doi-asserted-by":"crossref","unstructured":"Desjardins A, Gromeier M II, Beaubier JEH, Bolognesi N, Friedman DP, AH, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150\u201361.","DOI":"10.1056\/NEJMoa1716435"},{"issue":"4","key":"760_CR67","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ana.10688","volume":"54","author":"J Voges","year":"2003","unstructured":"Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol. 2003;54(4):479\u201387.","journal-title":"Ann Neurol"},{"key":"760_CR68","unstructured":"S. Spinraza\u00ae (nusinersen) injection for intrathecal use, Biogen - prescribing information [Internet]. 2024. https:\/\/www.spinraza.com\/PI. cited 2024 Aug 1]. Available from."},{"key":"760_CR69","unstructured":"Q. Qalsody\u00ae (tofersen) injection for intrathecal use, Biogen - prescribing information [Internet]. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215887s000lbl.pdf. cited 2024 July 29]. Available from."},{"key":"760_CR70","unstructured":"B. Brineura\u00ae (cerliponase alfa) injection for intraventricular use, Biomarin - Prescribing Information [Internet]. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761052lbl.pdf. cited 2024 July 27]. Available from."},{"issue":"11","key":"760_CR71","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","volume":"25","author":"JL Rubenstein","year":"2007","unstructured":"Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, et al. Phase I study of intraventricular administration of Rituximab in patients with recurrent CNS and Intraocular lymphoma. J Clin Oncol. 2007;25(11):1350\u201356.","journal-title":"J Clin Oncol"},{"issue":"5","key":"760_CR72","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1182\/blood-2012-07-440974","volume":"121","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013;121(5):745\u201351.","journal-title":"Blood"},{"issue":"1","key":"760_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-022-01383-4","volume":"15","author":"K Kramer","year":"2022","unstructured":"Kramer K, Pandit-Taskar N, Kushner BH, Zanzonico P, Humm JL, Tomlinson U, et al. Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies. J Hematol Oncol. 2022;15(1):165.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"760_CR74","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11060-022-04235-w","volume":"162","author":"KR Tringale","year":"2023","unstructured":"Tringale KR, Wolden SL, Karajannis M, Haque S, Pasquini L, Yildirim O, et al. Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma. J Neuro-Oncol. 2023;162(1):69\u201378.","journal-title":"J Neuro-Oncol"},{"issue":"14","key":"760_CR75","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. 2024;390(14):1290\u201398.","journal-title":"N Engl J Med"},{"issue":"3","key":"760_CR76","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s10549-019-05170-7","volume":"175","author":"NB Figura","year":"2019","unstructured":"Figura NB, Rizk VT, Mohammadi H, Evernden B, Mokhtari S, Yu HM, et al. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res Treat. 2019;175(3):781\u201388.","journal-title":"Breast Cancer Res Treat"},{"key":"760_CR77","doi-asserted-by":"publisher","first-page":"102046","DOI":"10.1016\/j.ctrv.2020.102046","volume":"88","author":"F Zagouri","year":"2020","unstructured":"Zagouri F, Zoumpourlis P, Rhun EL, Bartsch R, Zografos E, Apostolidou K, et al. Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: a metanalysis with meta-regression. Cancer Treat Rev. 2020;88:102046.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"760_CR78","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/neuonc\/noac180","volume":"25","author":"F Oberkampf","year":"2022","unstructured":"Oberkampf F, Gutierrez M, Grati OT, Rhun \u00c9L, Tr\u00e9dan O, Turbiez I, et al. Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis. Neuro-Oncol. 2022;25(2):365\u201374.","journal-title":"Neuro-Oncol"},{"issue":"3","key":"760_CR79","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/noac195","volume":"25","author":"PU Kumthekar","year":"2022","unstructured":"Kumthekar PU, Avram MJ, Lassman AB, Lin NU, Lee E, Grimm SA, et al. A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro-Oncol. 2022;25(3):557\u201365.","journal-title":"Neuro-Oncol"},{"issue":"4","key":"760_CR80","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","volume":"29","author":"ICG Oliva","year":"2023","unstructured":"Oliva ICG, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023;29(4):898\u2013905.","journal-title":"Nat Med"},{"key":"760_CR81","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.breast.2023.04.008","volume":"69","author":"AM Lazaratos","year":"2023","unstructured":"Lazaratos AM, Maritan SM, Quaiattini A, Darlix A, Ratosa I, Ferraro E, et al. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. Breast. 2023;69:451\u201368.","journal-title":"Breast"},{"issue":"5","key":"760_CR82","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/0006-3223(95)00180-8","volume":"39","author":"R Pietrowsky","year":"1996","unstructured":"Pietrowsky R, Str\u00fcben C, M\u00f6lle M, Fehm HL, Born J. Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans. Biol Psychiatry. 1996;39(5):332\u201340.","journal-title":"Biol Psychiatry"},{"issue":"10","key":"760_CR83","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.psyneuen.2004.04.003","volume":"29","author":"C Benedict","year":"2004","unstructured":"Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004;29(10):1326\u201334.","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"760_CR84","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a Pilot clinical trial. Arch Neurol. 2012;69(1):29\u201338.","journal-title":"Arch Neurol"},{"issue":"4","key":"760_CR85","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1161\/HYPERTENSIONAHA.113.02860","volume":"63","author":"I Derad","year":"2014","unstructured":"Derad I, Sayk F, Lehnert H, Marshall L, Born J, Nitschke M. Intranasal Angiotensin II in humans reduces blood pressure when Angiotensin II type 1 receptors are blocked. Hypertension. 2014;63(4):762\u201367.","journal-title":"Hypertension"},{"issue":"15","key":"760_CR86","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.3390\/cancers14153669","volume":"14","author":"X Guo","year":"2022","unstructured":"Guo X, Yang X, Wu J, Yang H, Li Y, Li J, et al. Tumor-treating fields in glioblastomas: past, present, and future. Cancers. 2022;14(15):3669.","journal-title":"Cancers"},{"issue":"1","key":"760_CR87","doi-asserted-by":"publisher","first-page":"vdz035","DOI":"10.1093\/noajnl\/vdz035","volume":"2","author":"KG Holste","year":"2019","unstructured":"Holste KG, Orringer DA. Laser interstitial thermal therapy. Neuro-Oncol Adv. 2019;2(1):vdz035.","journal-title":"Neuro-Oncol Adv"},{"issue":"9","key":"760_CR88","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/s41417-024-00775-7","volume":"31","author":"T Oishi","year":"2024","unstructured":"Oishi T, Koizumi S, Kurozumi K. Mesenchymal stem cells as therapeutic vehicles for glioma. Cancer Gene Ther. 2024;31(9):1306\u201314.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"760_CR89","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11912-024-01519-4","volume":"26","author":"AR Valerius","year":"2024","unstructured":"Valerius AR, Webb LM, Sener U. Novel clinical trials and approaches in the management of glioblastoma. Curr Oncol Rep. 2024;26(5):439\u201365.","journal-title":"Curr Oncol Rep"},{"issue":"14","key":"760_CR90","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMe2401307","volume":"390","author":"MR Jenkins","year":"2024","unstructured":"Jenkins MR, Drummond KJ. CAR T-Cell therapy for glioblastoma. N Engl J Med. 2024;390(14):1329\u201332.","journal-title":"N Engl J Med"},{"key":"760_CR91","doi-asserted-by":"publisher","first-page":"1227816","DOI":"10.3389\/fddev.2023.1227816","volume":"3","author":"WM Pardridge","year":"2023","unstructured":"Pardridge WM. Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier. Front Drug Deliv. 2023;3:1227816.","journal-title":"Front Drug Deliv"},{"issue":"1","key":"760_CR92","doi-asserted-by":"publisher","first-page":"2261509","DOI":"10.1080\/19420862.2023.2261509","volume":"15","author":"HP Grimm","year":"2023","unstructured":"Grimm HP, Schumacher V, Sch\u00e4fer M, Imhof-Jung S, Freskg\u00e5rd PO, Brady K, et al. Delivery of the BrainshuttleTM amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. mAbs. 2023;15(1):2261509.","journal-title":"mAbs"},{"issue":"1","key":"760_CR93","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","volume":"81","author":"J Niewoehner","year":"2014","unstructured":"Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81(1):49\u201360.","journal-title":"Neuron"},{"issue":"1","key":"760_CR94","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1038\/s41467-023-40681-4","volume":"14","author":"KS Chew","year":"2023","unstructured":"Chew KS, Wells RC, Moshkforoush A, Chan D, Lechtenberg KJ, Tran HL, et al. CD98hc is a target for brain delivery of biotherapeutics. Nat Commun. 2023;14(1):5053.","journal-title":"Nat Commun"},{"issue":"760","key":"760_CR95","doi-asserted-by":"publisher","first-page":"eadi 2245","DOI":"10.1126\/scitranslmed.adi2245","volume":"16","author":"SJ Barker","year":"2024","unstructured":"Barker SJ, Thayer MB, Kim C, Tatarakis D, Simon MJ, Dial R, et al. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier. Sci Transl Med. 2024;16(760):eadi 2245.","journal-title":"Sci Transl Med"},{"key":"760_CR96","doi-asserted-by":"crossref","unstructured":"Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545).","DOI":"10.1126\/scitranslmed.aay1359"},{"issue":"12","key":"760_CR97","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.medj.2022.09.007","volume":"3","author":"S Edavettal","year":"2022","unstructured":"Edavettal S, Cejudo-Martin P, Dasgupta B, Yang D, Buschman MD, Domingo D, et al. Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis. Med. 2022;3(12):860\u201382.e15.","journal-title":"Med"},{"issue":"9","key":"760_CR98","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s11095-007-9379-0","volume":"24","author":"AR Jones","year":"2007","unstructured":"Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res. 2007;24(9):1759\u201371.","journal-title":"Pharm Res"},{"issue":"4","key":"760_CR99","first-page":"311","volume":"5","author":"P Zhao","year":"2022","unstructured":"Zhao P, Zhang N, An Z. Engineering antibody and protein therapeutics to cross the blood-brain barrier. Antib Ther. 2022;5(4):311\u201331.","journal-title":"Antib Ther"},{"key":"760_CR100","doi-asserted-by":"publisher","first-page":"1360302","DOI":"10.3389\/fddev.2024.1360302","volume":"4","author":"AS Haqqani","year":"2024","unstructured":"Haqqani AS, B\u00e9langer K, Stanimirovic DB. Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria. Front Drug Deliv. 2024;4:1360302.","journal-title":"Front Drug Deliv"},{"issue":"7816","key":"760_CR101","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41586-020-2453-z","volume":"583","author":"AC Yang","year":"2020","unstructured":"Yang AC, Stevens MY, Chen MB, Lee DP, St\u00e4hli D, Gate D, et al. Physiological blood-brain transport is impaired with age by a shift in transcytosis. Nature. 2020;583(7816):425\u201330.","journal-title":"Nature"},{"issue":"2","key":"760_CR102","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neuron.2015.09.036","volume":"88","author":"N Bien-Ly","year":"2015","unstructured":"Bien-Ly N, Boswell CA, Jeet S, Beach TG, Hoyte K, Luk W, et al. Lack of Widespread BBB disruption in Alzheimer\u2019s disease models: focus on therapeutic antibodies. Neuron. 2015;88(2):289\u201397.","journal-title":"Neuron"},{"key":"760_CR103","unstructured":"Torres VO, Pizzo ME, Chan D, Dugas JC, Huynh D, Joy D, et al. Transferrin receptor-mediated transport at the blood-brain barrier is elevated during early development and maintained across aging and in an Alzheimer\u2019s mouse model. J Cereb Blood Flow Metab. 2025;271678X251361997."},{"issue":"2","key":"760_CR104","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.chembiol.2023.09.008","volume":"31","author":"G Pornnoppadol","year":"2024","unstructured":"Pornnoppadol G, Bond LG, Lucas MJ, Zupancic JM, Kuo YH, Zhang B, et al. Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs. Cell Chem Biol. 2024;31(2):361\u201372.e8.","journal-title":"Cell Chem Biol"},{"issue":"4","key":"760_CR105","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/j.1471-4159.2008.05492.x","volume":"106","author":"M Demeule","year":"2008","unstructured":"Demeule M, Currie J, Bertrand Y, Ch\u00e9 C, Nguyen T, R\u00e9gina A, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. J Neurochem. 2008;106(4):1534\u201344.","journal-title":"J Neurochem"},{"issue":"12","key":"760_CR106","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","volume":"26","author":"P Kumthekar","year":"2020","unstructured":"Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, et al. ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clin Cancer Res. 2020;26(12):2789\u201399.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"760_CR107","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s11095-009-9964-5","volume":"26","author":"FC Thomas","year":"2009","unstructured":"Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, et al. Uptake of ANG1005, a Novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res. 2009;26(11):2486\u201394.","journal-title":"Pharm Res"},{"issue":"6","key":"760_CR108","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1078-0432.CCR-12-2481","volume":"19","author":"J Drappatz","year":"2013","unstructured":"Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res. 2013;19(6):1567\u201376.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"760_CR109","doi-asserted-by":"publisher","first-page":"vdae186","DOI":"10.1093\/noajnl\/vdae186","volume":"6","author":"C Dmello","year":"2024","unstructured":"Dmello C, Brenner A, Piccioni D, Wen PY, Drappatz J, Mrugala M, et al. Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma. Neuro-Oncol Adv. 2024;6(1):vdae186.","journal-title":"Neuro-Oncol Adv"},{"issue":"1","key":"760_CR110","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1158\/1535-7163.MCT-14-0399","volume":"14","author":"A Regina","year":"2015","unstructured":"Regina A, Demeule M, Tripathy S, Lord-Dufour S, Currie JC, Iddir M, et al. ANG4043, a Novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in Mice. Mol Cancer Ther. 2015;14(1):129\u201340.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"760_CR111","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1172\/JCI70647","volume":"124","author":"M Demeule","year":"2014","unstructured":"Demeule M, Beaudet N, R\u00e9gina A, Besserer-Offroy \u00c9, Murza A, T\u00e9treault P, et al. Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. J Clin Investig. 2014;124(3):1199\u2013213.","journal-title":"J Clin Investig"},{"issue":"261","key":"760_CR112","doi-asserted-by":"publisher","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","volume":"6","author":"YJ Yu","year":"2014","unstructured":"Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med. 2014;6(261):261ra154.","journal-title":"Sci Transl Med"},{"issue":"615","key":"760_CR113","doi-asserted-by":"publisher","first-page":"eabj 4011","DOI":"10.1126\/scitranslmed.abj4011","volume":"13","author":"Y Meng","year":"2021","unstructured":"Meng Y, Reilly RM, Pezo RC, Trudeau M, Sahgal A, Singnurkar A, et al. MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. Sci Transl Med. 2021;13(615):eabj 4011.","journal-title":"Sci Transl Med"},{"issue":"22","key":"760_CR114","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1111\/bph.14021","volume":"174","author":"DB Yadav","year":"2017","unstructured":"Yadav DB, Maloney JA, Wildsmith KR, Fuji RN, Meilandt WJ, Solanoy H, et al. Widespread brain distribution and activity following i.c.v. infusion of anti-\u03b2-secretase (BACE1) in nonhuman primates. Br J Pharmacol. 2017;174(22):4173\u201385.","journal-title":"Br J Pharmacol"},{"issue":"84","key":"760_CR115","doi-asserted-by":"publisher","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","volume":"3","author":"YJ Yu","year":"2011","unstructured":"Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3(84):84ra44.","journal-title":"Sci Transl Med"},{"issue":"2","key":"760_CR116","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20131660","volume":"211","author":"N Bien-Ly","year":"2014","unstructured":"Bien-Ly N, Yu YJ, Bumbaca D, Elstrott J, Boswell CA, Zhang Y, et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med. 2014;211(2):233\u201344.","journal-title":"J Exp Med"},{"key":"760_CR117","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejpb.2016.01.009","volume":"101","author":"K Gadkar","year":"2016","unstructured":"Gadkar K, Yadav DB, Zuchero JY, Couch JA, Kanodia J, Kenrick MK, et al. Mathematical PKPD and safety model of bispecific TfR\/BACE1 antibodies for the optimization of antibody uptake in brain. Eur J Pharm Biopharm. 2016;101:53\u201361.","journal-title":"Eur J Pharm Biopharm"},{"issue":"8","key":"760_CR118","doi-asserted-by":"publisher","first-page":"116038","DOI":"10.1016\/j.celrep.2025.116038","volume":"44","author":"RC Wells","year":"2025","unstructured":"Wells RC, Akkapeddi P, Chan D, Joy D, Moshkforoush A, Chau R, et al. Dual targeting of transferrin receptor and CD98hc enhances brain exposure of large molecules. Cell Rep. 2025;44(8):116038.","journal-title":"Cell Rep"},{"issue":"1","key":"760_CR119","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41531-025-01117-6","volume":"11","author":"S An","year":"2025","unstructured":"An S, McInnis JJ, Kim D, Li Y, Tasdemir-Yilmaz O, Ahn J, et al. A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies. npj Park\u2019s Dis. 2025;11(1):254.","journal-title":"npj Park\u2019s Dis"},{"issue":"11","key":"760_CR120","doi-asserted-by":"publisher","first-page":"100338","DOI":"10.1016\/j.crmeth.2022.100338","volume":"2","author":"JW Shin","year":"2022","unstructured":"Shin JW, An S, Kim D, Kim H, Ahn J, Eom J, et al. Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier. Cell Rep Methods. 2022;2(11):100338.","journal-title":"Cell Rep Methods"},{"issue":"7","key":"760_CR121","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3390\/pharmaceutics14071452","volume":"14","author":"A Yogi","year":"2022","unstructured":"Yogi A, Hussack G, van FH, Haqqani AS, Delaney CE, Brunette E, et al. Brain delivery of IGF1R5, a single-domain antibody targeting insulin-like growth factor-1 receptor. Pharmaceutics. 2022;14(7):1452.","journal-title":"Pharmaceutics"},{"issue":"3","key":"760_CR122","doi-asserted-by":"publisher","first-page":"e22208","DOI":"10.1096\/fj.202101644R","volume":"36","author":"W Alata","year":"2022","unstructured":"Alata W, Yogi A, Brunette E, Delaney CE, van FH, Hussack G, et al. Targeting insulin-like growth factor-1 receptor (IGF1R) for brain delivery of biologics. Faseb J. 2022;36(3):e22208.","journal-title":"Faseb J"},{"issue":"2","key":"760_CR123","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1023\/A:1007049806660","volume":"20","author":"SI Rapoport","year":"2000","unstructured":"Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol. 2000;20(2):217\u201330.","journal-title":"Cell Mol Neurobiol"},{"issue":"1\u20132","key":"760_CR124","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.brainres.2004.04.034","volume":"1014","author":"RC Brown","year":"2004","unstructured":"Brown RC, Egleton RD, Davis TP. Mannitol opening of the blood-brain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin. Brain Res. 2004;1014(1\u20132):221\u201327.","journal-title":"Brain Res"},{"key":"760_CR125","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.addr.2014.01.008","volume":"72","author":"M Aryal","year":"2014","unstructured":"Aryal M, Arvanitis CD, Alexander PM, McDannold N. Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv Drug Deliv Rev. 2014;72:94\u2013109.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"760_CR126","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/cancers16010236","volume":"16","author":"M Pinkiewicz","year":"2024","unstructured":"Pinkiewicz M, Pinkiewicz M, Walecki J, Zaczy\u0144ski A, Zawadzki M. Breaking Barriers in neuro-oncology: a scoping literature review on invasive and non-invasive techniques for blood-brain barrier disruption. Cancers. 2024;16(1):236.","journal-title":"Cancers"},{"issue":"17","key":"760_CR127","first-page":"4725","volume":"48","author":"EA Neuwelt","year":"1988","unstructured":"Neuwelt EA, Barnett PA, Hellstr\u00f6m I, Hellstr\u00f6m KE, Beaumier P, McCormick CI, et al. Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res. 1988;48(17):4725\u201329.","journal-title":"Cancer Res"},{"issue":"5","key":"760_CR128","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2967\/jnumed.118.218792","volume":"60","author":"WG Lesniak","year":"2019","unstructured":"Lesniak WG, Chu C, Jablonska A, Du Y, Pomper MG, Walczak P, et al. A distinct advantage to intraarterial delivery of 89Zr-bevacizumab in PET imaging of Mice with and without osmotic opening of the blood-brain barrier. J Nucl Med. 2019;60(5):617\u201322.","journal-title":"J Nucl Med"},{"issue":"3","key":"760_CR129","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11060-015-1998-4","volume":"126","author":"S Jackson","year":"2016","unstructured":"Jackson S, Anders NM, Mangraviti A, Wanjiku TM, Sankey EW, Liu A, et al. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neuro-Oncol. 2016;126(3):433\u201339.","journal-title":"J Neuro-Oncol"},{"key":"760_CR130","doi-asserted-by":"publisher","first-page":"120942","DOI":"10.1016\/j.biomaterials.2021.120942","volume":"275","author":"RM Linville","year":"2021","unstructured":"Linville RM, Komin A, Lan X, DeStefano JG, Chu C, Liu G, et al. Reversible blood-brain barrier opening utilizing the membrane active peptide melittin in vitro and in vivo. Biomaterials. 2021;275:120942.","journal-title":"Biomaterials"},{"issue":"1","key":"760_CR131","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/neuonc\/noab177","volume":"24","author":"MFM Pinto","year":"2021","unstructured":"Pinto MFM, Campbell SJ, Karali CS, Johanssen VA, Bristow C, Cheng VWT, et al. Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein. Neuro-Oncol. 2021;24(1):52\u201363.","journal-title":"Neuro-Oncol"},{"issue":"5","key":"760_CR132","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/17425247.2024.2369765","volume":"21","author":"B Hosten","year":"2024","unstructured":"Hosten B, Goutal S, Leterrier S, Corvo C, Breuil L, Barret O, et al. Brain delivery enabled by transient blood-brain barrier disruption induced by regadenoson: a PET imaging study. Expert Opin Drug Deliv. 2024;21(5):797\u2013807.","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"760_CR133","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/neuonc\/5.2.96","volume":"5","author":"MD Prados","year":"2003","unstructured":"Prados MD, Schold SC, Fine HA, Jaeckle K, Hochberg F, Mechtler L, et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-Oncol. 2003;5(2):96\u2013103.","journal-title":"Neuro-Oncol"},{"issue":"3","key":"760_CR134","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00280-005-0172-7","volume":"58","author":"K Warren","year":"2006","unstructured":"Warren K, Jakacki R, Widemann B, Aikin A, Libucha M, Packer R, et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the children\u2019s oncology group. Cancer Chemother Pharmacol. 2006;58(3):343.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"760_CR135","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12987-017-0088-8","volume":"15","author":"S Jackson","year":"2018","unstructured":"Jackson S, Weingart J, Nduom EK, Harfi TT, George RT, McAreavey D, et al. The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS. 2018;15(1):2.","journal-title":"Fluids Barriers CNS"},{"issue":"37","key":"760_CR136","doi-asserted-by":"publisher","first-page":"E8717","DOI":"10.1073\/pnas.1807105115","volume":"115","author":"CD Arvanitis","year":"2018","unstructured":"Arvanitis CD, Askoxylakis V, Guo Y, Datta M, Kloepper J, Ferraro GB, et al. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. Proc Natl Acad Sci. 2018;115(37):E8717\u201326.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"760_CR137","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ultrasmedbio.2019.09.010","volume":"46","author":"AN Pouliopoulos","year":"2020","unstructured":"Pouliopoulos AN, Wu SY, Burgess MT, Karakatsani ME, Kamimura HAS, Konofagou EE. A clinical system for non-invasive blood-brain barrier opening using a Neuronavigation-guided single-element focused ultrasound transducer. Ultrasound Med Biol. 2020;46(1):73\u201389.","journal-title":"Ultrasound Med Biol"},{"issue":"37","key":"760_CR138","doi-asserted-by":"publisher","first-page":"e2103280118","DOI":"10.1073\/pnas.2103280118","volume":"118","author":"P Anastasiadis","year":"2021","unstructured":"Anastasiadis P, Gandhi D, Guo Y, Ahmed AK, Bentzen SM, Arvanitis C, et al. Localized blood-brain barrier opening in infiltrating gliomas with MRI-guided acoustic emissions-controlled focused ultrasound. Proc Natl Acad Sci. 2021;118(37):e2103280118.","journal-title":"Proc Natl Acad Sci"},{"issue":"18","key":"760_CR139","doi-asserted-by":"publisher","first-page":"e2021915118","DOI":"10.1073\/pnas.2021915118","volume":"118","author":"SR Burks","year":"2021","unstructured":"Burks SR, Kersch CN, Witko JA, Pagel MA, Sundby M, Muldoon LL, et al. Blood-brain barrier opening by intracarotid artery hyperosmolar mannitol induces sterile inflammatory and innate immune responses. Proc Natl Acad Sci. 2021;118(18):e2021915118.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"760_CR140","doi-asserted-by":"publisher","first-page":"E75","DOI":"10.1073\/pnas.1614777114","volume":"114","author":"ZI Kovacs","year":"2017","unstructured":"Kovacs ZI, Kim S, Jikaria N, Qureshi F, Milo B, Lewis BK, et al. Disrupting the blood-brain barrier by focused ultrasound induces sterile inflammation. Proc Natl Acad Sci. 2017;114(1):E75\u201384.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"760_CR141","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11060-020-03425-8","volume":"151","author":"K Beccaria","year":"2021","unstructured":"Beccaria K, Sabbagh A, de GJ, Canney M, Carpentier A, Heimberger AB. Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors. J Neuro-Oncol. 2021;151(1):65\u201373.","journal-title":"J Neuro-Oncol"},{"issue":"9","key":"760_CR142","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.4049\/jimmunol.1901430","volume":"205","author":"JB Joiner","year":"2020","unstructured":"Joiner JB, Pylayeva-Gupta Y, Dayton PA. Focused ultrasound for immunomodulation of the tumor microenvironment. J Immunol. 2020;205(9):2327\u201341.","journal-title":"J Immunol"},{"issue":"6","key":"760_CR143","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.tins.2022.03.003","volume":"45","author":"O Jung","year":"2022","unstructured":"Jung O, Thomas A, Burks SR, Dustin ML, Frank JA, Ferrer M, et al. Neuroinflammation associated with ultrasound-mediated permeabilization of the blood-brain barrier. Trends Neurosci. 2022;45(6):459\u201370.","journal-title":"Trends Neurosci"},{"issue":"2","key":"760_CR144","first-page":"55","volume":"5","author":"M Liebert","year":"1990","unstructured":"Liebert M, Wahl RL, Lawless G, McKeever PE, Taren JA, Beierwaltes WH, et al. Direct stereotactic intracerebral injection of monoclonal antibodies and their fragments: a potential approach to brain tumor immunotherapy. Am J Physiol Imag. 1990;5(2):55\u201359.","journal-title":"Am J Physiol Imag"},{"issue":"8","key":"760_CR145","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/jnci\/81.8.570","volume":"81","author":"RK Jain","year":"1989","unstructured":"Jain RK. Delivery of Novel therapeutic agents in tumors: physiological Barriers and strategies. JNCI: J Natl Cancer Inst. 1989;81(8):570\u201376.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"760_CR146","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2014.10.034","volume":"197","author":"DJ Wolak","year":"2015","unstructured":"Wolak DJ, Pizzo ME, Thorne RG. Probing the extracellular diffusion of antibodies in brain using in vivo integrative optical imaging and ex vivo fluorescence imaging. J Control Release. 2015;197:78\u201386.","journal-title":"J Control Release"},{"issue":"4","key":"760_CR147","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41582-022-00621-0","volume":"18","author":"STS van","year":"2022","unstructured":"van STS, Nieland L, Chiocca EA, Broekman MLD. Advances in local therapy for glioblastoma - taking the fight to the tumour. Nat Rev Neurol. 2022;18(4):221\u201336.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"760_CR148","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1021\/mp300495e","volume":"10","author":"DJ Wolak","year":"2013","unstructured":"Wolak DJ, Thorne RG. Diffusion of macromolecules in the brain: implications for drug delivery. Mol Pharm. 2013;10(5):1492\u2013504.","journal-title":"Mol Pharm"},{"issue":"2","key":"760_CR149","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","volume":"5","author":"M Westphal","year":"2003","unstructured":"Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol. 2003;5(2):79\u201388.","journal-title":"Neuro-Oncol"},{"issue":"3","key":"760_CR150","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11060-020-03408-9","volume":"151","author":"RS D\u2019Amico","year":"2021","unstructured":"D\u2019Amico RS, Aghi MK, Vogelbaum MA, Bruce JN. Convection-enhanced drug delivery for glioblastoma: a review. J Neuro-Oncol. 2021;151(3):415\u201327.","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"760_CR151","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3171\/jns.1995.82.6.1021","volume":"82","author":"DM Lieberman","year":"1995","unstructured":"Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg. 1995;82(6):1021\u201329.","journal-title":"J Neurosurg"},{"issue":"3","key":"760_CR152","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3171\/2014.10.JNS14229","volume":"122","author":"RR Lonser","year":"2015","unstructured":"Lonser RR, Sarntinoranont M, Morrison PF, Oldfield EH. Convection-enhanced delivery to the central nervous system. J Neurosurg. 2015;122(3):697\u2013706.","journal-title":"J Neurosurg"},{"issue":"4","key":"760_CR153","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3171\/jns.2002.97.4.0905","volume":"97","author":"RR Lonser","year":"2002","unstructured":"Lonser RR, Walbridge S, Garmestani K, Butman JA, Walters HA, Vortmeyer AO, et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg. 2002;97(4):905\u201313.","journal-title":"J Neurosurg"},{"issue":"3","key":"760_CR154","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.3171\/2015.1.FOCUS14743","volume":"38","author":"W Wang","year":"2015","unstructured":"Wang W, Sivakumar W, Torres S, Jhaveri N, Vaikari VP, Gong A, et al. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals. Neurosurg Focus. 2015;38(3):E8.","journal-title":"Neurosurg Focus"},{"issue":"11","key":"760_CR155","doi-asserted-by":"publisher","first-page":"8788","DOI":"10.18632\/oncotarget.3554","volume":"6","author":"M Kaluzova","year":"2015","unstructured":"Kaluzova M, Bouras A, Machaidze R, Hadjipanayis CG. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget. 2015;6(11):8788\u2013806.","journal-title":"Oncotarget"},{"issue":"8","key":"760_CR156","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/neuonc\/now023","volume":"18","author":"T Shoji","year":"2016","unstructured":"Shoji T, Saito R, Chonan M, Shibahara I, Sato A, Kanamori M, et al. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models. Neuro-Oncol. 2016;18(8):1120\u201328.","journal-title":"Neuro-Oncol"},{"key":"760_CR157","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3389\/fonc.2020.01443","volume":"10","author":"R Huang","year":"2020","unstructured":"Huang R, Boltze J, Li S. Strategies for improved intra-arterial treatments targeting brain tumors: a systematic review. Front Oncol. 2020;10:1443.","journal-title":"Front Oncol"},{"issue":"1","key":"760_CR158","doi-asserted-by":"publisher","first-page":"bcr-2018","DOI":"10.1136\/bcr-2018-014469","volume":"12","author":"M Zawadzki","year":"2019","unstructured":"Zawadzki M, Walecki J, Kostkiewicz B, Kostyra K, Pearl MS, Solaiyappan M, et al. Real-time MRI guidance for intra-arterial drug delivery in a patient with a brain tumor: technical note. BMJ Case Rep. 2019;12(1):bcr-2018\u2013014469.","journal-title":"BMJ Case Rep"},{"issue":"6","key":"760_CR159","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/neurintsurg-2021-018190","volume":"14","author":"SR Chen","year":"2022","unstructured":"Chen SR, Chen MM, Ene C, Lang FF, Kan P. Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors. J neurointerventional Surg. 2022;14(6):533\u201338.","journal-title":"J neurointerventional Surg"},{"issue":"1","key":"760_CR160","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2045-8118-11-10","volume":"11","author":"T Brinker","year":"2014","unstructured":"Brinker T, Stopa E, Morrison J, Klinge P. A new look at cerebrospinal fluid circulation. Fluids Barriers CNS. 2014;11(1):10\u201310.","journal-title":"Fluids Barriers CNS"},{"issue":"2","key":"760_CR161","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.05.009","volume":"144","author":"P Calias","year":"2014","unstructured":"Calias P, Banks WA, Begley D, Scarpa M, Dickson P. Intrathecal delivery of protein therapeutics to the brain: a critical reassessment. Pharmacol Ther. 2014;144(2):114\u201322.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"760_CR162","doi-asserted-by":"publisher","first-page":"e85311","DOI":"10.1172\/jci.insight.85311","volume":"1","author":"DA Wolf","year":"2016","unstructured":"Wolf DA, Hesterman JY, Sullivan JM, Orcutt KD, Silva MD, Lobo M, et al. Dynamic dual-isotope molecular imaging elucidates principles for optimizing intrathecal drug delivery. JCI Insight. 2016;1(2):e85311.","journal-title":"JCI Insight"},{"key":"760_CR163","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.addr.2021.03.002","volume":"173","author":"GN Kouzehgarani","year":"2021","unstructured":"Kouzehgarani GN, Feldsien T, Engelhard HH, Mirakhur KK, Phipps C, Nimmrich V, et al. Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues. Adv Drug Deliv Rev. 2021;173:20\u201359.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"760_CR164","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1113\/JP275105","volume":"596","author":"ME Pizzo","year":"2018","unstructured":"Pizzo ME, Wolak DJ, Kumar NN, Brunette E, Brunnquell CL, Hannocks M, et al. Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery. J Physiol. 2018;596(3):445\u201375.","journal-title":"J Physiol"},{"key":"760_CR165","doi-asserted-by":"publisher","first-page":"114338","DOI":"10.1016\/j.addr.2022.114338","volume":"186","author":"M Khang","year":"2022","unstructured":"Khang M, Bindra RS, Saltzman WM. Intrathecal delivery and its applications in leptomeningeal disease. Adv Drug Deliv Rev. 2022;186:114338.","journal-title":"Adv Drug Deliv Rev"},{"key":"760_CR166","doi-asserted-by":"crossref","unstructured":"Papisov MI, Belov G VV, KS. Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS. Mol Pharm. 2013;10(5):1522\u201332.","DOI":"10.1021\/mp300474m"},{"issue":"1","key":"760_CR167","doi-asserted-by":"publisher","first-page":"e30341","DOI":"10.1371\/journal.pone.0030341","volume":"7","author":"P Calias","year":"2012","unstructured":"Calias P, Papisov M, Pan J, Savioli N, Belov V, Huang Y, et al. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One. 2012;7(1):e30341.","journal-title":"PLoS One"},{"key":"760_CR168","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46\u201351.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"760_CR169","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/hum.2017.026","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer C, Bell P, Katz N, Vite CH, Louboutin JP, Bote E, et al. Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals. Hum Gene Ther. 2018;29(1):15\u201324.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"760_CR170","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s13311-020-00864-z","volume":"17","author":"AS Wahl","year":"2020","unstructured":"Wahl AS, Correa D, Imobersteg S, Maurer MA, Kaiser J, Augath MA, et al. Targeting therapeutic antibodies to the CNS: a comparative study of intrathecal, intravenous, and subcutaneous anti-Nogo a antibody treatment after stroke in rats. Neurotherapeutics. 2020;17(3):1153\u201359.","journal-title":"Neurotherapeutics"},{"key":"760_CR171","doi-asserted-by":"publisher","first-page":"958543","DOI":"10.3389\/fphar.2022.958543","volume":"13","author":"AJVD Vyver","year":"2022","unstructured":"Vyver AJVD, Walz AC, Heins MS, Abdolzade-Bavil A, Kraft TE, Waldhauer I, et al. Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration. Front Pharmacol. 2022;13:958543.","journal-title":"Front Pharmacol"},{"issue":"2","key":"760_CR172","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1208\/s12248-024-00898-7","volume":"26","author":"S Wu","year":"2024","unstructured":"Wu S, Chang HY, Chowdhury EA, Huang HW, Shah DK. Investigation of antibody pharmacokinetics in the brain following intra-CNS administration and development of PBPK model to characterize the data. Aaps J. 2024;26(2):29.","journal-title":"Aaps J"},{"issue":"2","key":"760_CR173","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","volume":"101","author":"JL Rubenstein","year":"2003","unstructured":"Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2):466\u201368.","journal-title":"Blood"},{"issue":"2\u20133","key":"760_CR174","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1023\/A:1005996606073","volume":"38","author":"HB Coakham","year":"1998","unstructured":"Coakham HB, Kemshead JT. Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients. J Neuro-Oncol. 1998;38(2\u20133):225\u201332.","journal-title":"J Neuro-Oncol"},{"issue":"3","key":"760_CR175","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1208\/s12248-008-9055-2","volume":"10","author":"F Herv\u00e9","year":"2008","unstructured":"Herv\u00e9 F, Ghinea N, Scherrmann JM. CNS delivery via adsorptive transcytosis. Aaps J. 2008;10(3):455\u201372.","journal-title":"Aaps J"},{"issue":"5","key":"760_CR176","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1046\/j.1471-4159.1999.02002.x","volume":"73","author":"J Girod","year":"1999","unstructured":"Girod J, Fenart L, R\u00e9gina A, Dehouck MP, Hong G, Scherrmann JM, et al. Transport of cationized anti-tetanus Fab\u20192 fragments across an in vitro blood-brain barrier model: involvement of the transcytosis pathway. J Neurochem. 1999;73(5):2002\u201308.","journal-title":"J Neurochem"},{"issue":"1","key":"760_CR177","doi-asserted-by":"publisher","first-page":"8244","DOI":"10.1038\/ncomms9244","volume":"6","author":"S Lim","year":"2015","unstructured":"Lim S, Kim WJ, Kim YH, Lee S, Koo JH, Lee JA, et al. dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis. Nat Commun. 2015;6(1):8244.","journal-title":"Nat Commun"},{"key":"760_CR178","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","volume":"195","author":"TP Crowe","year":"2018","unstructured":"Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018;195:44\u201352.","journal-title":"Life Sci"},{"issue":"3","key":"760_CR179","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuroscience.2008.01.013","volume":"152","author":"RG Thorne","year":"2008","unstructured":"Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH. Delivery of interferon-\u03b2 to the monkey nervous system following intranasal administration. Neuroscience. 2008;152(3):785\u201397.","journal-title":"Neuroscience"},{"issue":"7","key":"760_CR180","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614\u201328.","journal-title":"Adv Drug Deliv Rev"},{"key":"760_CR181","doi-asserted-by":"crossref","unstructured":"Balyasnikova P IV, Ferguson MS, Han SD, Ahmed Y, Gutova AU, M, et al. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol Ther. 2014;22(1):140\u201348.","DOI":"10.1038\/mt.2013.199"},{"key":"760_CR182","doi-asserted-by":"crossref","unstructured":"Chauhan MB, Chauhan NB. Brain uptake of neurotherapeutics after intranasal versus intraperitoneal delivery in Mice. J Neurol Neurosurg. 2015;2(1).","DOI":"10.19104\/jnn.2015.91"},{"key":"760_CR183","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jconrel.2018.08.006","volume":"286","author":"NN Kumar","year":"2018","unstructured":"Kumar NN, Lochhead JJ, Pizzo ME, Nehra G, Boroumand S, Greene G, et al. Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: distribution, dose-response, and mechanisms of delivery. J Control Release. 2018;286:467\u201384.","journal-title":"J Control Release"},{"issue":"2","key":"760_CR184","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ymthe.2017.11.015","volume":"26","author":"D Alarc\u00f3n-Ar\u00eds","year":"2018","unstructured":"Alarc\u00f3n-Ar\u00eds D, Recasens A, Galofr\u00e9 M, Carballo-Carbajal I, Zacchi N, Ruiz-Bronchal E, et al. Selective \u03b1-synuclein knockdown in monoamine neurons by Intranasal oligonucleotide delivery: potential therapy for Parkinson\u2019s disease. Mol Ther. 2018;26(2):550\u201367.","journal-title":"Mol Ther"},{"issue":"4","key":"760_CR185","doi-asserted-by":"publisher","first-page":"e2200057120","DOI":"10.1073\/pnas.2200057120","volume":"120","author":"D Correa","year":"2023","unstructured":"Correa D, Scheuber MI, Shan H, Weinmann OW, Baumgartner YA, Harten A, et al. Intranasal delivery of full-length anti-Nogo-a antibody: a potential alternative route for therapeutic antibodies to central nervous system targets. Proc Natl Acad Sci U States Am. 2023;120(4):e2200057120.","journal-title":"Proc Natl Acad Sci U States Am"},{"issue":"18","key":"760_CR186","doi-asserted-by":"publisher","first-page":"e1807557","DOI":"10.1002\/adma.201807557","volume":"31","author":"D Wu","year":"2019","unstructured":"Wu D, Qin M, Xu D, Wang L, Liu C, Ren J, et al. A bioinspired platform for effective delivery of protein therapeutics to the central nervous system. Adv Mater. 2019;31(18):e1807557.","journal-title":"Adv Mater"},{"issue":"19","key":"760_CR187","doi-asserted-by":"publisher","first-page":"e1805697","DOI":"10.1002\/adma.201805697","volume":"31","author":"L Han","year":"2019","unstructured":"Han L, Liu C, Qi H, Zhou J, Wen J, Wu D, et al. Systemic delivery of monoclonal antibodies to the central nervous system for brain tumor therapy. Adv Mater. 2019;31(19):e1805697.","journal-title":"Adv Mater"},{"key":"760_CR188","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.3389\/fimmu.2019.03132","volume":"10","author":"M Qin","year":"2020","unstructured":"Qin M, Wang L, Wu D, Williams CK, Xu D, Kranz E, et al. Enhanced delivery of Rituximab into brain and lymph nodes using timed-release nanocapsules in non-human primates. Front Immunol. 2020;10:3132.","journal-title":"Front Immunol"},{"issue":"1","key":"760_CR189","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.1038\/s41467-020-19225-7","volume":"11","author":"JV Gregory","year":"2020","unstructured":"Gregory JV, Kadiyala P, Doherty R, Cadena M, Habeel S, Ruoslahti E, et al. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nat Commun. 2020;11(1):5687.","journal-title":"Nat Commun"},{"issue":"4","key":"760_CR190","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1021\/acs.bioconjchem.9b00085","volume":"30","author":"M Zheng","year":"2019","unstructured":"Zheng M, Huang M, Ma X, Chen H, Gao X. Harnessing exosomes for the development of brain drug delivery systems. Bioconjugate Chem. 2019;30(4):994\u20131005.","journal-title":"Bioconjugate Chem"},{"issue":"17","key":"760_CR191","first-page":"e2004381","volume":"8","author":"Y Li","year":"2021","unstructured":"Li Y, Teng X, Wang Y, Yang C, Yan X, Li J. Neutrophil delivered hollow titania covered persistent luminescent nanosensitizer for ultrosound augmented chemo\/immuno glioblastoma therapy. Adv Sci (Weinh, Baden-Wurttemberg, Ger). 2021;8(17):e2004381.","journal-title":"Adv Sci (weinh, Baden-Wurttemberg, Ger)"},{"issue":"11","key":"760_CR192","doi-asserted-by":"publisher","first-page":"108132","DOI":"10.1016\/j.isci.2023.108132","volume":"26","author":"L Schellhammer","year":"2023","unstructured":"Schellhammer L, Beffinger M, Salazar U, Laman JD, Buch T, Vom BJ. Exit pathways of therapeutic antibodies from the brain and retention strategies. iScience. 2023;26(11):108132.","journal-title":"iScience"},{"issue":"4","key":"760_CR193","doi-asserted-by":"publisher","first-page":"e0214404","DOI":"10.1371\/journal.pone.0214404","volume":"14","author":"R Nakano","year":"2019","unstructured":"Nakano R, Takagi-Maeda S, Ito Y, Kishimoto S, Osato T, Noguchi K, et al. A new technology for increasing therapeutic protein levels in the brain over extended periods. PLoS One. 2019;14(4):e0214404.","journal-title":"PLoS One"},{"issue":"1","key":"760_CR194","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12987-025-00624-1","volume":"22","author":"ML Cuypers","year":"2025","unstructured":"Cuypers ML, Jaspers T, Clerckx J, Leekens S, Cawthorne C, Bormans G, et al. Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein. Fluids Barriers CNS. 2025;22(1):11.","journal-title":"Fluids Barriers CNS"},{"issue":"5","key":"760_CR195","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.ultrasmedbio.2021.01.014","volume":"47","author":"M Olsman","year":"2021","unstructured":"Olsman M, Sereti V, M\u00fchlenpfordt M, Johnsen KB, Andresen TL, Urquhart AJ, et al. Focused ultrasound and microbubble treatment increases delivery of transferrin receptor-targeting liposomes to the brain. Ultrasound Med Biol. 2021;47(5):1343\u201355.","journal-title":"Ultrasound Med Biol"},{"key":"760_CR196","unstructured":"USFADA. Cancer clinical trial eligibility criteria: brain metastases [Internet]. 2020 July. https:\/\/www.fda.gov\/media\/121317\/download. cited 2025 Nov 16]. Available from. Silver Spring, MD: FDA."},{"issue":"3","key":"760_CR197","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10928-013-9301-9","volume":"40","author":"LE de","year":"2013","unstructured":"de LE. Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn. 2013;40(3):315\u201326.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-026-00760-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-026-00760-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-026-00760-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:08:43Z","timestamp":1770887323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12987-026-00760-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":197,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["760"],"URL":"https:\/\/doi.org\/10.1186\/s12987-026-00760-2","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors other than R.V are current employees of Genentech, Inc. R.V was an intern at Genentech, Inc. at the time of literature compilation. All authors may be stockholders of F. Hoffmann-La Roche AG.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}